Holen Sie sich die Stockscreener-App
7.17
2.43%
0.17
Handel nachbörslich:
7.54
0.37
+5.16%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BHC?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$7.00
Offen:
$7.05
24-Stunden-Volumen:
1.87M
Relative Volume:
0.93
Marktkapitalisierung:
$2.65B
Einnahmen:
$9.47B
Nettoeinkommen (Verlust:
$-178.00M
KGV:
-14.94
EPS:
-0.48
Netto-Cashflow:
$1.01B
1W Leistung:
+24.48%
1M Leistung:
+11.68%
6M Leistung:
+12.38%
1J Leistung:
+30.84%
1-Tages-Spanne:
$6.985
$7.18
1-Wochen-Bereich:
$5.68
$7.18
52-Wochen-Spanne:
$4.25
$9.85
Bausch Health Companies Inc Stock (BHC) Company Profile
Firmenname
Bausch Health Companies Inc
Sektor
Telefon
514-744-6792
Adresse
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Vergleichen Sie BHC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
7.17 | 2.59B | 9.47B | -178.00M | 1.01B | -0.48 |
|
ZTS
Zoetis Inc
|
152.44 | 66.38B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 46.20B | 29.96B | 957.25M | 5.31B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.69 | 42.99B | 14.26B | 1.98B | 0 | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 19.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.72 | 13.63B | 2.99B | 1.21B | 1.13B | 25.06 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-02 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2024-07-10 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-20 | Hochstufung | Jefferies | Hold → Buy |
| 2023-06-16 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2022-07-29 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-07-29 | Herabstufung | Truist | Buy → Hold |
| 2022-07-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-06-13 | Fortgesetzt | JP Morgan | Overweight |
| 2021-03-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-02-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-01-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-09-17 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-24 | Eingeleitet | Citigroup | Buy |
| 2020-04-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-01-22 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2019-12-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-02 | Eingeleitet | Goldman | Neutral |
| 2019-10-25 | Eingeleitet | Cowen | Outperform |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-15 | Hochstufung | TD Securities | Hold → Buy |
| 2019-07-19 | Eingeleitet | Wolfe Research | Outperform |
| 2019-06-11 | Fortgesetzt | Barclays | Overweight |
| 2019-05-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-01-02 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-11-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-13 | Hochstufung | Piper Jaffray | Underweight → Neutral |
Alle ansehen
Bausch Health Companies Inc Aktie (BHC) Neueste Nachrichten
Form PRE 14A Bausch Health Companies For: Oct 07 - StreetInsider
Durect and Bausch Health Merger on Track to Close in Q3 - AInvest
Bausch Health (BHC) Rebounds 15.8% on Bargain-Hunting - MSN
Bausch Health's Durect Acquisition: Strategic Valuation and Risk Mitigation in Biopharma M&A - AInvest
Biotech DURECT Gets $63M Buyout Offer from Bausch Health with $350M Future Payment Potential - Stock Titan
IBS in America: Despite advances, IBS remains a burden for many millions - Benzinga
Why Bausch Health Stock Surged By Nearly 20% (NYSE:BHC) - Seeking Alpha
Bausch Health reaffirms 2025 revenue target of $4.95B–$5.1B as debt reduction and pipeline expansion advance - MSN
Bausch Health Companies Inc. shares fall 1.65% premarket as TSX steadies with tech stocks rising. - AInvest
United States Epilepsy Drugs Market Trends and Company - GlobeNewswire
Is This a Bottoming Phase for Bausch Health Companies Inc.Intraday Trend Analysis for Fast Gains Released - metal.it
Bausch Health to Acquire DURECT Corporation in $63M Deal to Advance Liver Disease Treatment - MSN
Is Bausch Health Companies Inc. Forming a Consolidation BaseShort Term Buy Zone Stock Alerts Signal Entry - metal.it
Saudi Arabia OTC Artificial Tears Market Forecast and - GlobeNewswire
Saudi Arabia OTC Artificial Tears Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, Akorn, Alcon, Bausch Health, J&J, Nicox, Novartis, Santen Pharmaceutical, Sun Pharmaceutical - Yahoo Finance
Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners - The Daily Corinthian
Bausch Health's $100K GI Health Scholarship Program Empowers 10 Students Despite Medical Challenges - Stock Titan
Bausch Health Companies Inc. shares fall 2.95% intraday as Toronto stocks climb to fresh highs. - AInvest
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease - biomb.ca
Bausch Health Companies Inc. shares rise 2.68% intraday after Viatris Inc. appoints David Simmons to its Board of Directors. - AInvest
Liver Cirrhosis Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Pfizer, GlaxoSmithKline, Bausch Health, Bristol-Myers Squibb, Mallinckrodt, Cumberland - Barchart.com
Saudi Arabia Vision Care Market Forecast and Company - GlobeNewswire
Saudi Arabia Vision Care Market Forecast and Company Analysis Report 2025-2033 Featuring Essilor, J&J, Bausch Health, Novartis, Grand Vision, Carl Zeiss, Valeant, Paragon Vision Science, Menicon - Yahoo Finance
Is Bausch Health Companies Inc. a growth stock or a value stockFree Daily Trading Room Entry - Jammu Links News
What are the technical indicators suggesting about Bausch Health Companies Inc.Fastest-growing stock picks - Jammu Links News
What are analysts’ price targets for Bausch Health Companies Inc. in the next 12 monthsBuild a diversified portfolio for stability - Jammu Links News
What institutional investors are buying Bausch Health Companies Inc. stockBuild a winning portfolio with smart picks - Jammu Links News
What analysts say about Bausch Health Companies Inc. stockInvest confidently with professional guidance - Jammu Links News
Does Bausch Health Companies Inc. stock perform well during market downturnsGet timely alerts on market opportunities - Jammu Links News
How does Bausch Health Companies Inc. compare to its industry peersConsistently superior profits - Jammu Links News
What catalysts could drive Bausch Health Companies Inc. stock higher in 2025Track high-yield stocks before they peak - Jammu Links News
Lacklustre Performance Is Driving Bausch Health Companies Inc.'s (NYSE:BHC) 25% Price Drop - 富途牛牛
How many analysts rate Bausch Health Companies Inc. as a “Buy”Discover market opportunities with real-time data - Jammu Links News
What is the dividend policy of Bausch Health Companies Inc. stockRapid capital growth - Jammu Links News
Bausch Health Companies Inc. (NYSE:BHC) Q2 2025 Earnings Call Transcript - Insider Monkey
Bausch Health Companies Inc. Attempts Reversal From Key SupportNews Based Entry Opportunity Alerts Detected - metal.it
Real Time Data Flags Unusual Activity in Bausch Health Companies Inc.Profit Target Stock Opportunity Monitor Activated - metal.it
Bausch Health to acquire liver drug developer Durect for $1.75 per share - MSN
Bausch Health Companies Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Bausch Health Companies Inc. Bounces Off Moving Average SupportFast Return Equity Trade Forecast Points to Small Caps - metal.it
Bausch Health to redeem ~$602M of outstanding notes due 2026 - MSN
Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat - MSN
How strong is Bausch Health Companies Inc. company’s balance sheetBest Dividend Tips With High Returns - Jammu Links News
Bausch Health’s Earnings Climb, But The Road Ahead Stays Cloudy - Finimize
Bausch Health Companies Inc. SEC 10-Q Report - TradingView
Bausch: Q2 Earnings Snapshot - Connecticut Post
Glaucoma Global Clinical Trials Market Landscape Report 2025 Featuring Alcon, AbbVie, Santen Pharmaceutical, Pfizer, Kowa, Viatris, Merck, Novartis, Senju Pharmaceutical, Bausch Health - Yahoo Finance
Bausch Health Companies Inc (BHC) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... By GuruFocus - Investing.com Canada
Bausch Health's Strategic Moves: Debt Reduction and Pipeline Expansion as Drivers of Shareholder Value in 2025 - AInvest
Finanzdaten der Bausch Health Companies Inc-Aktie (BHC)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):